Drugs / Armolipid Plus
Trials 0
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT03277079 Comparator | Oct → Dec 2017 | coronary artery disorder | University of Roma La Sapienza | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Armolipid Plus | “The aim of this study was to evaluate whether the combination of low-dose statin (LDS) plus ezetimibe (EZE) or LDS plus nutraceutical (Armolipid Plus [ALP] containing red yeast...” PMID 30420184 ↗ Oct 2018 |
| Known as | ALP | “The aim of this study was to evaluate whether the combination of low-dose statin (LDS) plus ezetimibe (EZE) or LDS plus nutraceutical (Armolipid Plus [ALP] containing red yeast...” PMID 30420184 ↗ Oct 2018 |
| Modality | Other / unclassified | “LDS plus nutraceutical (Armolipid Plus [ALP] containing red yeast rice, policosanol, and berberine)” PMID 30420184 ↗ Oct 2018 |